Basel, November 17, 2011 The discovery of a new class of dual-acting antimalarial compounds - the imidazolopiperazines (IZPs) was published in the journal Science online, at the Science Express website today1. The findings report on compounds that target both liver and blood infections, attacking the Plasmodium parasite at both stages in its reproduction cycle.
The findings describe how scientists developed a novel assay to determine liver stage activity of candidate small molecules, then used the assay and other tools to identify and optimize a chemical scaffold with activity on both blood- and liver-stage parasites in malaria mouse models. Several other compound classes, also with dual activity, are described and released by Novartis through ChEMBL Neglected Tropical Disease at https://www.ebi.ac.uk/chemblntd.
For over a decade, Novartis has engaged in the front ranks of combating malaria, pioneering the not-for-profit supply of our antimalarial treatment Coartem to the public sector of endemic countries, commented Joseph Jimenez, CEO of Novartis. These new findings further demonstrate our innovative and sustainable research commitment in this important area which has become integral to our corporate strategy for social responsibility.
Scientists from the Novartis Institutes for BioMedical Research, through the Genomics Institute of the Novartis Research Foundation (GNF) and the Novartis Institute for Tropical Diseases (NITD), collaborated with the Scripps Research Institute and Swiss Tropical and Public Health Institute, and received support from the Wellcome Trust, Singapore Economic Development Board, and Medicines for Malaria Venture. This is the second new class of antimalarials discovered by the same group in the last two years and holds promise as a next-generation treatment for malaria if confirmed.
Novartis is committed t
|Contact: Mariellen Gallagher|
Novartis Institutes for BioMedical Research